This Combined Synopsis/Solicitation opportunity from Department Of Health And Human Services was posted on November 24, 2025. The submission period has ended. Browse the details below for market research, or find similar active opportunities.
Independent Validation and Verification (IV&V) Services for the REACT Program
Contract Overview
Solicitation details, issuing organization, response deadlines, documents, and interested companies for this government contract opportunity.
Active Opportunities Like This One
AI Contract Overview
The Advanced Research Projects Agency for Health (ARPA-H) has issued solicitation 75N99226R00001 for Independent Validation and Verification (IV&V) services to support its Resilient Extended Automatic Cell Therapies (REACT) program, focusing on developing wireless implantable medical devices for chronic disease surveillance and treatment. The contract, with an estimated total value of approximately $19.5 million, covers a base period from February 23, 2026, through February 22, 2027, and includes two successive option periods extending through August 22, 2028. The REACT program’s key products include the “Living Pharmacy” device, which delivers tunable therapeutic molecules on demand, and the “Living Sentinel” device, engineered to monitor disease biomarker status. Central to this contract is the IV&V of engineered or differentiated cell lines critical to these devices, ensuring their standardization and reproducibility to meet FDA requirements and enable scalable manufacturing. The contract is structured as a time-and-materials agreement, encompassing labor, travel, special studies, and related direct costs. The contractor will be responsible for characterizing unmodified pancreatic cells and REACT performer cells, validating the therapeutic outputs and biomarker detection capabilities of the devices, and delivering comprehensive technical reports on critical quality attributes (CQAs), process parameters, and materials, all aligned with regulatory and manufacturing standards. Deliverables include monthly updates, interim and final progress reports, and technical assessments. Work performance is primarily at contractor or designated performer sites with virtual government oversight, spanning a multi-year period. Compliance with a broad suite of Federal Acquisition Regulation (FAR) clauses and Department of Health and Human Services (HHS) deviations is required, emphasizing ethical business conduct, system security, fair labor standards, and small business subcontracting goals. Evaluation of proposals will prioritize technical and management approaches equally, with price as a tertiary factor, and award will be based on best value. The submission deadline for proposals is January 5, 2026, with stringent formatting and content guidelines for technical, management, and price volumes. Electronic invoice submission via the Department of Treasury Invoice Processing Platform (IPP) is mandated, and subcontracting plans consistent with HHS requirements are also necessary given the contract’s anticipated size.
General Info
Agency
Place of Performance
Set-Aside
Documents
3AI Contract Breakdown
Uniform Contract FormatSign up to view the full breakdown with detailed analysis of each section.
View Full BreakdownThis one is closed. Find the next one like it.
Open contracts like this one, right now:
- DETROIT JCC-2026-40 BACKFLOW PREVENTER TESTING, MAINTENANCE & INSPECTIONOpen now, due in 192 days
- Certified Legal Interpretation and TranslationOpen now, due in 19 days
Ask CLEATUS
I've read this contract. Ask me anything.
Timeline
Combined Synopsis
Contract was awarded
Submission Closed
Organization & Contact Information
Full Description
This is a combined synopsis/solicitation for commercial products or commercial services prepared in accordance with part 12. This announcement constitutes the only solicitation. Offers are being requested and a separate written solicitation will not be issued.
Please refer to the attachments for full details.
The Advanced Research Projects Agency for Health (ARPA-H) Resilient Systems Office (RSO) requires independent validation and verification (IV&V) services for its Resilient Extended Automatic Cell Therapies (REACT) program. The REACT program is developing wireless implantable medical devices for the surveillance and treatment of chronic diseases that can ultimately make it to the commercial market as an affordable health care device. The objective is for the devices to interface with patients through a software platform, allowing for confirmation of therapy delivery or current disease status. The “Living Pharmacy” device will deliver tunable therapeutic molecules on demand, while the “Living Sentinel” device will track disease biomarker status. A critical component of the devices is engineered and/or differentiated cell lines (herein, “cells”) that deliver therapies or track biomarker status, respectively. IV&V is required by the REACT team to achieve standardization and reproducibility of cells so the program can scale up the manufacturing capability for the Living Pharmacy and Living Sentinel.
More opportunities from Department Of Health And Human Services → Advanced Research Projects Agency For Health (arpa-H)
Same awarding agency
Get AI-powered intelligence on the opportunities still open
Every solicitation package arrives shredded into a compliance breakdown and matched to your past performance, with incumbent history and alerts on amendments and award.
Join 900+ contractors already using CLEATUS
